Methods of vaccine administration
This invention relates to a method of treating a dog for canine diseases comprising administering to the dog therapeutically effective amounts of a vaccine, wherein the vaccine comprises viral antigens, a bacterin, or both, and wherein the vaccine is administered subcutaneously or orally according to the schedules provided herein.
1. A method of eliciting protective titer against Canine Distemper (CD) virus in a serum of a dog comprising administering to the dog therapeutically effective amounts of vaccine, wherein the vaccine comprises a viral antigen, and, optionally, a bacterin, and wherein the vaccine is administered orally in a first dose and orally in a second dose, said second dose being administered about 7 days to about 35 days following administration of said first dose, and wherein said viral antigen is CD virus, and one or more of canine adenovirus type 2 (CAV-2), canine parainfluenza (CPI) virus, canine parvovirus (CPV), and canine coronavirus (CCV), and wherein said optional bacterin is selected from the group consisting of Leptospira canicola, L. grippotyphosa, L. icterohaemorrhagiae, L. pomona, L. bratislava, and Bordetella bronchiseptica, wherein said protecting titer against CD is greater than or equal to 1:32 at three weeks after said second vaccination.
2. The method according to claim 1 , wherein the vaccine comprises the viral antigens CD virus, CAV-2, CPI virus, and CPV.
3. The method according to claim 2 , wherein the vaccine comprises the bacterins Leptospira canicola, L. grippotyphosa, L. icterohaemorrhagiae, and L. pomona.
4. The method according to claim 3 , wherein the vaccine further comprises the viral antigen CCV.
5. The method according to claim 1 , wherein the vaccine comprises the viral antigens CD virus, CAV-2, CPI virus, and CPV, and the bacterin Bordetella bronchiseptica.
6. The method according to claim 1 , wherein the canine diseases comprise one or more of 1) CD caused by CD virus; 2) infectious canine hepatitis caused by CAV-1; 3) respiratory disease caused by CAV-2 or respiratory CCV; 4) CPI caused by CPI virus; 5) enteritis caused by CCV or CPV; 6) leptospirosis caused by Leptospira canicola, L. grippotyphosa, L. icterohaemorrhagiae, L. pomona, or L. bratislava; and 7) infectious tracheobronchitis (“kennel cough”) caused by Bordetella bronchiseptica.
7. The method according to claim 6 , wherein the diseases comprise 1) CD caused by CD virus; 2) infectious canine hepatitis caused by CAV-1; 3) respiratory disease caused by CAV-2; 4) CPI caused by CPI virus; 5) and canine parvoviral enteritis caused by CPV.
8. The method according to claim 1 , wherein the viral antigens are present in the following ranges of amounts: for CD virus, about 10 2 TCID 50 to about 10 8 TCID 50 , inclusive; for CAV-2, about 10 2 TCID 50 to about 10 8 TCID 50 , inclusive; for CPV, about 10 3 TCID 50 to about 10 10 TCID 50 , inclusive; for CPI virus, about 10 3 TCID 50 to about 10 10 TCID 50 , inclusive; and for CCV, at least about 100 relative units (RU) per dose.
9. The method according to claim 1 , wherein the viral antigens are present in the following ranges of amounts: for CD virus, about 10 3 TCID 50 to about 10 6 TCID 50 , inclusive; for CAV-2, about 10 3 TCID 50 to about 10 6 TCID 50 , inclusive; for CPV, about 10 6 TCID 50 to about 10 9 TCID 50 , inclusive; for CPI virus, about 10 5 TCID 50 to about 10 9 TCID 50 , inclusive; and for CCV, about 1,000 RU to about 4,500 RU per dose.
10. The method according to claim 1 , wherein the viral antigens are present in the following ranges of amounts: for CD virus, about 10 4 TCID 50 to about 10 5 TCID 50 , inclusive; for CAV-2, about 10 4 TCID 50 to about 10 5 TCID 50 , inclusive; for CPV, about 10 7 TCID 50 to about 10 8 TCID 50 , inclusive; and for CPI virus, about 10 6 TCID 50 to about 10 8 TCID 50 , inclusive.
11. The method according to claim 1 , wherein each Leptospira is present in a range of amounts from about 100 nephelometric units (NU) to about 3,500 NU per vaccine dose, and wherein the Bordetella bronchiseptica is present in a range from about 3×10 6 to about 3×10 11 cells inclusive.
12. The method according to claim 1 , wherein each Leptospira is present in a range of amounts from about 200 NU to about 2,000 NU per dose, and wherein the Bordetella bronchiseptica is present in a range from about from about 3×10 7 to about 3×10 10 cells inclusive.
13. The method according to claim 1 , wherein the Bordetella bronchiseptica is present in a range from about 3×10 8 to about 3×10 9 cells inclusive.
14. The method according to claim 1 , wherein the second dose is administered about 3 weeks after the first dose.
15. The method according to claim 1 further comprising a third dose administered from 7 to 35 days, inclusive, after the second dose.
16. The method according to claim 15 , wherein the third dose is administered about 3 weeks after the second dose.
17. The method according to claim 1 further comprising an annual dose administered about one year after the first dose.
18. The method according to claim 17 , wherein annual doses administered after said annual dose are administered repeatedly about one year after the immediately prior annual dose.
19. The method according to claim 1 , wherein the viral antigen is a combination of CDV, CPV and CAV-2.
20. The method according to claim 1 , wherein the viral antigen comprises modified live viruses or attenuated viruses.
21. The method according to claim 1 , wherein the composition is non-adjuvanted.